Moreover, crizotinib treatment of PR+BC mice furthered the decrease of DNMT3a levels in the PFC tissues as com-pared to untreated PR+BC mice (p=0.0058) (Fig. 6A). The gene discussed is DNMT3A; the disease is breast cancer.